EGFR and non-small cell lung carcinoma: Erlotinib is an oral, reversible inhibitor of wild-type and mutant EGFR (Figure 1) indicated for the first-line treatment of metastatic NSCLC harboring deletion 19 (del19) or exon 21 (L858R) substitution EGFR mutations (OSI Pharmaceuticals, LLC, 2015).